Affiliated Treatment Facilities
- West Los Angeles VA Medical Center
01. Doctor Overview
Doctor Overview
Dr. Robert B. Cameron is globally recognized as an expert on pleural mesothelioma. He is the director of the Comprehensive Mesothelioma Program at the University of California, Los Angeles (UCLA).
The Comprehensive Mesothelioma Program is one of the world’s leading centers for all stages and types of mesothelioma. The program specializes in lung-sparing surgery, such as pleurectomy and decortication (P/D), and cutting-edge treatments, including immunotherapy and cryoablation. In his role with this program, Dr. Cameron treats mesothelioma patients and collaborates with other doctors on research.
Dr. Cameron also currently holds the following positions:
- Chief of thoracic surgery at West Los Angeles VA Medical Center in Los Angeles, California
- Cardiothoracic surgery and surgical oncology professor at David Geffen School of Medicine at UCLA
- Principle investigator for UCLA of the American College of Surgeons Oncology Group
- Director of the lung volume reduction surgery program at UCLA
Dr. Cameron has done clinical research on mesothelioma, video-assisted surgery, immunotherapy and other related topics. He has written over 35 peer-reviewed articles and more than 38 book chapters. Dr. Cameron has also reviewed articles for medical journals, such as the Annals of Thoracic Surgery and the Journal of the National Cancer Institute.
Improving mesothelioma patients’ quality of life is an integral part of Dr. Cameron’s work. For instance, he was among the first thoracic surgeons to oppose a complex and invasive surgery known as extrapleural pneumonectomy (EPP). Research has supported P/D over EPP because of the risks of lung removal.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Thoracic Surgery
Other Interests & Specialties: Mesothelioma, thoracic oncology, surgical oncology, thoracic pain management, esophageal cancer, esophageal surgery, lung cancer, minimally-invasive and robotic-assisted surgery, thymoma, immunotherapy and angiogenesis, bronchial and esophageal stents, thoracic outlet syndrome and lung volume reduction surgery.
Certifications, Awards & Accolades: Co-founder and former director of the Mesothelioma Applied Research Foundation, Chair, Organizer and Moderator of International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma, Fellow of the American College of Surgeons, Scientific Advisor for the Pacific Mesothelioma Center, Super Doctor of Southern California award by Key Professional, Inc. (2012 – 2024), America’s Top Doctors award by Castle Connolly (2007 – 2021), Former Co-Investigator for Specialized Program of Research Excellence (SPORE) in Lung Cancer at UCLA, Chairman of the Preferred Oncology Network of California Lung Cancer Committee, Member of the Society of Surgical Oncology, Society of Thoracic Surgeons, Western Thoracic Surgical Association, American Society of Clinical Oncology, International Association for the Study of Lung Cancer, Pacific Coast Surgical Association, International Society for Biologic Therapy of Cancer, American Association for Cancer Research, International College of Surgeons
Education & Experience:
- Fellowship in Surgical Oncology at Surgery Branch, National Cancer Institute, National Institutes of Health
- Residency in General Surgery at UCLA Health
- Residency in Cardiothoracic Surgery at NewYork-Presbyterian/Weill Cornell Medical Center
- Medical Degree at David Geffen School of Medicine at UCLA
03. Publications
Publications
Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma. Curr Oncol. 2023 May 23;30(6):5195–200.
The majority of patients with resectable incidental lung cancers are ineligible for lung cancer screening. JTCVS Open. 2023 Mar;13:379–88.
Transvertebral Cryoablation of a Paraesophageal Mass in a Patient with Metastatic Malignant Pleural Mesothelioma. UCLA Radiological Sciences Proceedings. 2023;3(2).
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022 Jun;23(6):758–67.
Disclaimer: Mesothelioma.com has no affiliation with and is not endorsed or sponsored by Dr. Robert B. Cameron. The contact information above is listed for informational purposes only. You have the right to contact Dr. Cameron directly.
